AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06547437
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 0.9% 100 cc
Trial: NCT06220188
Drug: [177Lu]Lu-PSMA I&T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
Trial: NCT04272372
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO and local therapy
Trial: NCT04882124
Drug: CSJ117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
Trial: NCT04882124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
Trial: NCT04999839
Drug: NDI-034858 study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NDI-034858 2 mg oral capsules.
Trial: NCT04999839
Drug: NDI-034858 study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NDI-034858 5 mg oral capsules.
Trial: NCT04999839
Drug: NDI-034858 study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NDI-034858 15 mg oral capsules.
Trial: NCT04999839
Drug: NDI-034858 study drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NDI-034858 30 mg (2\*15 mg) oral capsules.
Trial: NCT06317558
Drug: Other drugs for neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
Trial: NCT05141344
Drug: Melatonin 3 MG Oral Tablet
RxNorm normalized name: melatonin 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it will be given orally one hour preoperatively
Trial: NCT05141344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar-coated tablets will be given one hour preoperatively
Trial: NCT06451302
Drug: cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
Trial: NCT05664828
Drug: SN132D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manganese-based macromolecular MRI contrast agent
Trial: NCT04770428
Drug: MEDI7352
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
Trial: NCT04770428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
Trial: NCT05454410
Drug: MIJ821 Subcutaneous Injection - high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
Trial: NCT05454410
Drug: Placebo Subcutaneous Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
Trial: NCT04905836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient solution
Trial: NCT04993430
Drug: HRS8807、SHR6390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS8807 in combination with SHR6390
Trial: NCT05106127
Drug: EG-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Repurposed Drug
Trial: NCT05444556
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT05734703
Drug: Nutraceutical Topical
RxNorm normalized name: ZINC OXIDE 154 mg in 1 mL TOPICAL LOTION [Ultraceuticals Ultra UV Protective Daily Moisturising]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
Trial: NCT06118385
Drug: BEN8744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Trial: NCT06118385
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Trial: NCT05451095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05742126
Drug: HSK36273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple continuous IV infusion ascending doses for 5 days
Trial: NCT05742126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05742126
Drug: Heparin sodium injection
RxNorm normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching positive control
Trial: NCT00258141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06430697
Drug: paracetamol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
Trial: NCT05633563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of capsules
Trial: NCT04877496
Drug: History of exposure to anti-CD20 treatment since 01/01/2010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treatment history of anti-CD20 treatment since 01/01/2010
Trial: NCT05091073
Drug: NNC0385-0434
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
Trial: NCT05284136
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.
Trial: NCT04159493
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Application
Trial: NCT04159493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Application
Trial: NCT00049790
Drug: recombinant human Angiostatin protein
RxNorm normalized name: surfactant protein-D homotrimer, recombinant fragment human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06518668
Drug: Cyclophosphamide LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)
Trial: NCT04835389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT05239650
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
Trial: NCT05715840
Drug: SG001 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg，Q3W，IV infusion
Trial: NCT05715840
Drug: SG001 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q3W，IV infusion
Trial: NCT05928637
Drug: D745, D759, D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO for 5 days
Trial: NCT04929067
Drug: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
RxNorm normalized name: pertussis, inactivated, whole cell, combinations with toxoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Trial: NCT05859776
Drug: AXT107 Mid Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single suprachoroidal injection of AXT107 (0.250 mg/eye)
Trial: NCT04723394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Trial: NCT05930119
Drug: HMPL-453
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg HMPL-453
Trial: NCT05246644
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
Trial: NCT05199142
Drug: SDI-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
Trial: NCT05199142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
Trial: NCT01003405
Drug: KUC-7483
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06247046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Powder
Trial: NCT05116111
Drug: SYHA1402 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 tablets, oral, twice daily
Trial: NCT05116111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, twice daily
Trial: NCT06162988
Drug: 68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
Trial: NCT01255501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04702256
Drug: Administration of methylprednisolone, paracetamol and dexchlorpheniramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
Trial: NCT05766969
Drug: CBD/PEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
Trial: NCT05766969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An inactive compound.
Trial: NCT05872685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative placebo, 300 mg IV infusion
Trial: NCT05761405
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
Trial: NCT00002328
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04761601
Drug: UCT-01-097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally available kinase inhibitor
Trial: NCT00663624
Drug: Usual care as prescribed by the ED physicians.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
Trial: NCT05933213
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucocorticoids
Trial: NCT06133049
Drug: No DMTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with MS not exposed to any DMTs during pregnancy
Trial: NCT05124067
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive normal saline.
Trial: NCT05498792
Drug: CBL0137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
Trial: NCT05098028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Twice Daily
Trial: NCT04319367
Drug: Investigational Medicinal Product
RxNorm normalized name: Percy Medicine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human monoclonal antibody (mAb) or placebo
Trial: NCT05089409
Drug: ATB1651, 2 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Trial: NCT05089409
Drug: ATB1651, 5 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Trial: NCT05089409
Drug: ATB1651, 10 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Trial: NCT05925920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of placebo comparator
Trial: NCT05833906
Drug: CKR-051 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered 5 g of CKR-051.
Trial: NCT05833906
Drug: CKR-051 Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered 10 g of CKR-051.
Trial: NCT05833906
Drug: CKR-051 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered 10 g of CKR-051.
Trial: NCT05833906
Drug: CKR-051 Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered 10 g of CKR-051.
Trial: NCT05833906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator.
Trial: NCT04854395
Drug: Marcain 5 mg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
Trial: NCT04663321
Drug: MK-1942
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
Trial: NCT04663321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose matched placebo capsules BID orally over 4 weeks.
Trial: NCT06538584
Drug: Caffeine citrate 10mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 10mg/kg Caffeine citrate 15 minutes post surgery.
Trial: NCT06538584
Drug: 0.9% Sodium Citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
Trial: NCT03324867
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Trial: NCT03324867
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Trial: NCT00000756
Drug: Lymphocytes, Activated
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05806060
Drug: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
Trial: NCT05806060
Drug: nab-paclitaxel, with maintenance of capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
Trial: NCT04714554
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 500-mg tablets; oral administration.
Trial: NCT04775485
Drug: DAY101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
Trial: NCT04750070
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
Trial: NCT04750070
Drug: Blood Transfusion
RxNorm normalized name: Blood transfusion, auxiliary products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
Trial: NCT05857215
Drug: amilo-5MER
RxNorm normalized name: amilomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
Trial: NCT04530747
Drug: Placebo oral capsule + PAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Trial: NCT06339281
Drug: apatinib mesylate+Capecitabine Tablets
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;
Trial: NCT05707520
Drug: enteric-coated mycophenolate (MPAs)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunosuppression protocol with enteric-coated mycophenolate sodium
Trial: NCT05204394
Drug: VM-1500A-LAI
RxNorm normalized name: laidlomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
Trial: NCT05841277
Drug: LY3819469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04938908
Drug: Ophthalmic Probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
Trial: NCT04938908
Drug: Opthalmic Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
Trial: NCT05119790
Drug: [14C] BIIB122 ([14C] DNL151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose
Trial: NCT02153541
Drug: Antipyrine-benzocaine otic solution
RxNorm normalized name: antipyrine / benzocaine Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
Trial: NCT04833049
Drug: [14C]TAK-994 Intravenous Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-994 intravenous infusion.
Trial: NCT04833049
Drug: [14C]TAK-994 Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-994 oral suspension.
Trial: NCT04600752
Drug: Augmentin (ES)-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
Trial: NCT05413668
Drug: RVP-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of RVP-001
Trial: NCT05413668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of saline placebo